Introduction/Treatment Overview of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Panelists discuss how subcutaneous anti-CD38 monoclonal antibodies are reshaping frontline multiple myeloma treatment by improving efficacy, tolerability, and patient convenience across both transplant-eligible and ineligible populations.
Recent advancements in the treatment of newly diagnosed multiple myeloma have significantly reshaped clinical strategies, particularly in both transplant-eligible and transplant-ineligible populations. Among the most notable developments has been the integration of anti-CD38 monoclonal antibodies into standard regimens. These agents, when combined with backbone therapies like such as lenalidomide, bortezomib, and dexamethasone, have shown substantial efficacy and have become central to many frontline treatment approaches.
The availability of subcutaneous formulations, particularly of anti-CD38 therapies, has marked a pivotal shift in the treatment landscape. These formulations offer not only robust clinical activity but also enhanced convenience and tolerability, which is especially important in a chronic disease setting. For many clinicians, the subcutaneous delivery has become a foundational component in treatment planning, improving the overall patient experience while maintaining therapeutic intensity. This has allowed for greater flexibility and broader use of these regimens across different patient groups.
While guidelines now list multiple recommended and preferred options, a unifying approach has emerged: prioritizing regimens that balance high response rates with manageable toxicity. The growing consensus is that subcutaneous monoclonal antibodies, when used in combination with established agents, offer a compelling first-line strategy. As newer data from trials like such as CEPHEUS and PERSEUS continue to emerge, these regimens are expected to evolve further. However, the emphasis remains on delivering effective, well-tolerated, and patient-centric treatment—ensuring that the benefits of innovation in multiple myeloma reach patients early in their therapeutic journey.
